Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Neural Therapeutics Inc. ( (TSE:NURL) ) is now available.
Neural Therapeutics has applied to the Canadian Securities Exchange for approval to exercise its option to acquire the remaining 69.25% of CWE European Holdings, operator of German CBD retailer Hanf.com, which would give Neural full ownership and mark its shift into a fully commercial entity. The proposed “Fundamental Change” transaction requires multiple regulatory and shareholder approvals, including a May 1, 2026 meeting where investors will vote on the deal, a 4-for-1 share consolidation, a name change to Hanf.com Inc., board elections, and equity incentive plans.
To support the transaction, an affiliated CWE entity plans a non-brokered private placement of up to $600,000 through units priced at $0.08, with attached warrants, that will be exchanged into securities of the post-transaction issuer. Management positions the deal and concurrent financing as steps to strengthen access to capital markets, accelerate Hanf.com’s retail expansion and brand development in Germany, and enhance long-term shareholder value, though completion remains contingent on satisfying all regulatory and minority approval conditions.
More about Neural Therapeutics Inc.
Neural Therapeutics Inc. is a Toronto-based company transitioning from a pure research and development focus into a commercially operating business. Through its association with CWE European Holdings Inc., which operates as Hanf.com, it is targeting Germany’s regulated CBD and hemp retail market, aiming to build a leading specialty CBD retail platform with growing revenues and profitable operations.
Average Trading Volume: 192,740
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$2.53M
Learn more about NURL stock on TipRanks’ Stock Analysis page.